首页> 外文期刊>BMC Cardiovascular Disorders >The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design
【24h】

The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design

机译:REFER(EchocaRdiogram的参考)协议:前瞻性验证临床决策规则,NT-proBNP或它们的组合,用于诊断初级保健中的心力衰竭。基本原理和设计

获取原文
           

摘要

Background Heart failure is a major cause of mortality and morbidity. As mortality rates are high, it is important that patients seen by general practitioners with symptoms suggestive of heart failure are identified quickly and treated appropriately. Identifying patients with heart failure or deciding which patients need further tests is a challenge. All patients with suspected heart failure should be diagnosed using objective tests such as echocardiography, but it is expensive, often delayed, and limited by the significant skill shortage of trained echocardiographers. Alternative approaches for diagnosing heart failure are currently limited. Clinical decision tools that combine clinical signs, symptoms or patient characteristics are designed to be used to support clinical decision-making and validated according to strict methodological procedures. The REFER Study aims to determine the accuracy and cost-effectiveness of our previously derived novel, simple clinical decision rule, a natriuretic peptide assay, or their combination, in the triage for referral for echocardiography of symptomatic adult patients who present in general practice with symptoms suggestive of heart failure. Methods/design This is a prospective, Phase II observational, diagnostic validation study of a clinical decision rule, natriuretic peptides or their combination, for diagnosing heart failure in primary care. Consecutive adult primary care patients 55 years of age or over presenting to their general practitioner with a chief complaint of recent new onset shortness of breath, lethargy or peripheral ankle oedema of over 48 hours duration, with no obvious recurrent, acute or self-limiting cause will be enrolled. Our reference standard is based upon a three step expert specialist consensus using echocardiography and clinical variables and tests. Discussion Our clinical decision rule offers a potential solution to the diagnostic challenge of providing a timely and accurate diagnosis of heart failure in primary care. Study results will provide an evidence-base from which to develop heart failure care pathway recommendations and may be useful in standardising care. If demonstrated to be effective, the clinical decision rule will be of interest to researchers, policy makers and general practitioners worldwide. Trial registration ISRCTN17635379
机译:背景技术心力衰竭是死亡和发病的主要原因。由于死亡率很高,因此必须快速识别并适当治疗普通医生所见的具有心力衰竭症状的患者。识别心力衰竭患者或确定哪些患者需要进一步检查是一个挑战。所有怀疑有心力衰竭的患者均应使用客观检查(例如超声心动图)进行诊断,但由于昂贵的超声心动图检查人员技能严重不足,价格昂贵,经常被延误并且受到限制。当前,诊断心力衰竭的替代方法受到限制。结合临床体征,症状或患者特征的临床决策工具旨在支持临床决策并根据严格的方法学程序进行验证。 REFER研究旨在确定我们先前得出的新颖,简单的临床决策规则,利钠肽测定法或它们的组合的准确度和成本效益,将其转诊用于有症状的有症状的成年患者,这些患者通常会出现超声心动图提示心力衰竭。方法/设计这是对临床决策规则,利钠肽或它们的组合进行的前瞻性,II期观察性,诊断性验证研究,用于诊断初级保健中的心力衰竭。 55岁或以上的连续成人初级保健患者就诊于全科医生,主要症状是最近新发作的呼吸急促,嗜睡或周围踝部水肿持续时间超过48小时,没有明显的复发,急性或自限性病因将被注册。我们的参考标准基于使用超声心动图,临床变量和测试的三步专家共识。讨论我们的临床决策规则为及时,准确地诊断初级保健中的心力衰竭的诊断挑战提供了潜在的解决方案。研究结果将为制定心力衰竭护理途径建议提供依据,并可能有助于标准化护理。如果证明有效,则临床决策规则将引起全球研究人员,政策制定者和全科医生的关注。试用注册ISRCTN17635379

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号